Showing results (201-210 of 220) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patientsG M Clark, M C Mathieu, M A Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancerC G Moertel, T R Fleming, J S Macdonald, et al.
The New England Journal of Medicine|February 8, 1990
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinomaC G Moertel, T R Fleming, J S Macdonald, et al.
Cancer|November 1, 1983
Cooperative groups and community hospitals. Measurement of impact in the community hospitalsC B Begg, M Zelen, P P Carbone, et al.
Cancer|January 15, 1980
Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adultsR T Skeel, W Costello, J M Bennett, et al.
Cancer|November 1, 1987
A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG studyG Falkson, L M Ryan, L A Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomasE C Borden, D A Amato, C Rosenbaum, et al.
The New England Journal of Medicine|March 26, 1992
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancerR R Love, R B Mazess, H S Barden, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot studyG Falkson, D Von Hoff, D Klaassen, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|January 1, 1992
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cellsM R Albertini, D F Gibson, S P Robinson, et al.
Pageof 22